Recently Viewed
Clear All$3.80
$-36.54
(-90.58%)
As on 21-Jul-2023 09:30EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$27 Mln
Revenue (TTM)
$12 Mln
Net Profit (TTM)
$-15 Mln
ROE
-2.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.7
Industry P/E
--
EV/EBITDA
-0.1
Div. Yield
0 %
Debt to Equity
-0.9
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
6,273,220
CFO
CN¥-287.12 Mln
EBITDA
CN¥-433.88 Mln
Net Profit
CN¥-487.01 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AnPac Bio-Medical Science - ADR
| -18.8 | 2.7 | -24.5 | -35.4 | -67.7 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
AnPac Bio-Medical Science - ADR
| -80.8 | -77.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the... People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is headquartered in Shanghai, the People's Republic of China. Read more
Co-Founder, Co-CEO & Co-Chairman
Dr. Chris Chang Yu
Co-Founder, Co-CEO & Co-Chairman
Dr. Chris Chang Yu
Headquarters
Lishui
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of AnPac Bio-Medical Science Co Ltd - ADR is $3.80 (NASDAQ) as of 21-Jul-2023 09:30 EDT. AnPac Bio-Medical Science Co Ltd - ADR has given a return of -67.67% in the last 3 years.
Since, TTM earnings of AnPac Bio-Medical Science Co Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of AnPac Bio-Medical Science Co Ltd - ADR are Rs -- and Rs -- as of 05-Apr-2026.
AnPac Bio-Medical Science Co Ltd - ADR has a market capitalisation of $ 27 Mln as on 21-Jul-2023. As per SEBI classification, it is a Small Cap company.
Before investing in AnPac Bio-Medical Science Co Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.